← Back to Search

Chemotherapy for Stomach Cancer

Phase 2

Waitlist Available

Led By Lorenzo Ferri

Research Sponsored by McGill University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histological diagnosis of adenocarcinoma of the stomach, gastroesophageal junction (GEJ), or lower third of the esophagus

Stage IB (T1N1 only), II, IIIA, IIIB, and IV (T4N1 only)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will study the side effects and effectiveness of two chemotherapy regimens given before surgery to patients with stomach cancer.

Who is the study for?

This trial is for adults with potentially removable tumors in the stomach, gastroesophageal junction, or lower esophagus. They should be physically able to do light work and have no major organ issues or conditions that would prevent surgery. Pregnant women and those unable to consent are excluded.Check my eligibility

What is being tested?

The study tests a chemotherapy mix (Taxotere, Cisplatin, and 5-Fluorouracil) before surgery on patients with certain stomach cancers. It aims to see if this improves surgical outcomes and survival without radiotherapy.See study design

What are the potential side effects?

Possible side effects include reactions to chemo like nausea, fatigue, hair loss, low blood cell counts leading to increased infection risk or bleeding problems, kidney function changes, and potential hearing impairment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is in the stomach, GEJ, or lower esophagus.

Select...

My cancer is at a specific stage between early and advanced.

Select...

I can walk and care for myself without help.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor

392 Previous Clinical Trials

984,475 Total Patients Enrolled

Lorenzo FerriPrincipal InvestigatorMcGill University

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00763646 — Phase 2

Gastroesophageal Junction Adenocarcinoma Research Study Groups:

Gastroesophageal Junction Adenocarcinoma Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00763646 — Phase 2

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00763646 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible to join this experiment?

"Per the information available on clinicaltrials.gov, this study is not currently recruiting patients. It was originally posted on April 1st, 2007 and last updated on October 20th, 2008. Although this particular trial isn't looking for new participants, there are 994 other trials that are."

Answered by AI

Could you please elaborate on the safety of this procedure for patients?

"Given that this is a Phase 2 trial, and thus there is only limited evidence for safety but no efficacy data, our team gives this treatment a score of 2."

Answered by AI

Would anyone who is not yet 50 years old be able to qualify for this research program?

"This specific trial is only for patients aged 19-80, whereas there are 13 other clinical trials that cater to a younger demographic and 993 trials for senior citizens."

Answered by AI

For whom is this clinical trial designed?

"This study is admitting 30 patients with adenocarcinoma aged 19 and 80. Most notable, candidates should meet the following criteria: The tumour must be deemed by the team to be potentially resectable. This includes imaging studies (detailed below) to clinically stage the tumour and rule-out the presence of metastatic disease, and includes a preoperative laparoscopic evaluation., Stage IB (T1N1 only), II, IIIA, IIIB, and IV (T4N1 only), Life expectancy greater than 3 months, ECOG performance status of 1 or better (i.e. restricted in"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

2007. "Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00763646.

All > Adenocarcinoma > Flu